Clinical trial
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)
NCT06673069 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 20, 2024
- Completion date
- December 3, 2025
- Enrollment
- 1 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.